Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

American Lung Association Teams With The AAAAI To Award Research Grants To Study Allergic Respiratory Disease
The American Lung Association and the American Academy of Allergy, Asthma & Immunology are partnering to further clinical research to benefit the estimated 40 to 50 million of Americans living with allergic diseases such as asthma.

KCI Announces FDA Clearance Of ABThera™ Open Abdomen Dressing
Kinetic Concepts, Inc. (NYSE: KCI) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its ABThera™ Open Abdomen Dressing. Earlier this year, the FDA cleared the ABThera™ Open Abdomen Negative Pressure Therapy Unit. Together, the ABThera™ Open Abdomen Negative Pressure Therapy System will be indicated for temporary bridging of abdominal wall openings where primary closure is not possible or repeat abdominal entries are necessary. The intended use of the system is for open abdominal wounds, with exposed viscera, including but not limited to abdominal compartment syndrome.
News of the day
Budget Solution Must Protect Health Care For Children
Dr. Dev GnanaDev, president of the California Medical Association, issued the following statement after Gov. Arnold Schwarzenegger called on the state Legislature to swiftly enact his proposed budget cuts.
Sexual Health

Development Of DNA Drugs Gives Hope To Lupus Patients

A generation of DNA-like compounds, class R inhibitory oligonucleotides (INH-ODNs), have been shown to effectively inhibit cells responsible for the chronic autoimmune condition lupus. Researchers writing in BioMed Central"s open access journal Arthritis Research & Therapy have demonstrated the anti-inflammatory effects of the INH-ODNs in both in vitro and mouse experiments. Petar Lenert, from the University of Iowa, worked with a team of researchers to develop and test the compounds. He said, "The increased potency of class R INH-ODNs for certain cells involved in lupus flare-ups will help patients by providing specific inhibition, yet allowing them to generate a protective immune response when needed". Lenert and his colleagues found that their INH-ODN drugs, composed of double-stranded DNA-like analogues carrying autoimmune-inhibitory sequences, were able to selectively reduce the activity of autoreactive B cells and dendritic cells. When given to mice with lupus, the compounds delayed death and reduced kidney damage. Systemic lupus erythematosus, more commonly known simply as lupus, is thought to affect around a million people in the USA, but prevalence varies by country and ethnicity. It is much more common in women than men and there is currently no known cure. During periodic "flares", the immune system of people with the condition mounts an attack on cells and tissues throughout the body, resulting in a range of symptoms including the characteristic "butterfly rash" across the cheeks. With further testing, Lenert and his colleagues hope that class R INH-ODNs may become another weapon in the fight against the disease. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas lpr/lpr mice in vivo Petar Lenert, Kei Yasuda, Liliana Busconi, Patrice Nelson, Courtney Fleenor, Radhika S Ratnabalasuriar, Peter L Nagy, Robert F Ashman, Ian R Rifkin and Ann Marshak-Rothstein Arthritis Research & Therapy http://arthritis-research.com/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009